title: HLA-A11-mediated protection from NK cell-mediated lysis: role of HLA-A11-presented peptides.
abstract: The capacity of MHC class I to protect target cells from NK is well established, but the mechanism by which these molecules influence NK recognition and the physical properties associated with this function remain poorly defined. We have examined this issue using as a model the HLA-A11 allele. HLA-A11 expression correlated with reduced susceptibility to NK and interferon-activated cytotoxicity in transfected sublines of the A11-defective Burkitt's lymphoma WW2-BL and the HLA class I A,B-null C1R cell line. Protection was also achieved by transfection of HLA-A11 in the peptide processing mutant T2 cells line (T2/A11), despite a very low expression of the transfected product at the cell surface. Induction of surface HLA-A11 by culture of T2/A11 cells at 26 degrees C or in the presence of beta 2m did not affect lysis, whereas NK sensitivity was restored by culture in the presence of HLA-All-binding synthetic peptides derived from viral or cellular proteins. Acid treatment rendered T2/A11 and C1R/A11 cells sensitive to lysis, but protection was restored after preincubation with peptide preparations derived from surface stripping of T2/A11 cells. Similar peptide preparations from T2 cells had no effect. The results suggest that NK protection is mediated by HLA-A11 molecules carrying a particular set of peptides that are translocated to the site of MHC class I assembly in the ER in a TAP-independent fashion.
authors.affiliation: Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden.
authors.forename: R
authors.initials: R
authors.lastname: Gavioli
authors.forename: Q J
authors.initials: QJ
authors.lastname: Zhang
authors.forename: M G
authors.initials: MG
authors.lastname: Masucci
mesh_terms: D017951:Antigen Presentation / Q000235:genetics*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D015536:Down-Regulation; D015234:HLA-A Antigens / Q000096:biosynthesis / Q000235:genetics* / Q000494:pharmacology*; D059870:HLA-A11 Antigen; D006801:Humans; D007372:Interferons / Q000037:antagonists & inhibitors; D007694:Killer Cells, Natural / Q000187:drug effects*; D010455:Peptides / Q000276:immunology* / Q000494:pharmacology; D011485:Protein Binding / Q000276:immunology; D014407:Tumor Cells, Cultured
chemical_list: D015234:HLA-A Antigens; D059870:HLA-A11 Antigen; D010455:Peptides; D007372:Interferons